Euro Gen Follistatin 344, 1mg

Euro-Gen

Research chemical / peptide reagent

Recombinant human Follistatin 344 protein for in vitro research

Supplied and labelled as a research Use Only recombinant protein, not as a medicinal product, medical device, cosmetic or food.
Not authorised or licensed by the MHRA, EMA, FDA or other medicines regulators for any therapeutic indication.
Use is governed by general chemical and biological safety regulations and institutional policies applicable to laboratory reagents in the relevant jurisdiction.
Researchers and institutions are responsible for ensuring that any use of this reagent complies with local laws, ethics approvals and applicable professional or anti Doping codes.

Supplied and labelled as a research Use Only recombinant protein, not as a medicinal product, medical device, cosmetic or food.
Not authorised or licensed by the MHRA, EMA, FDA or other medicines regulators for any therapeutic indication.
Use is governed by general chemical and biological safety regulations and institutional policies applicable to laboratory reagents in the relevant jurisdiction.
Researchers and institutions are responsible for ensuring that any use of this reagent complies with local laws, ethics approvals and applicable professional or anti Doping codes.

Recombinant human Follistatin 344 protein for in vitro research

Description

Euro-Gen Follistatin 344, 1mg is a recombinant research protein supplied as a lyophilised powder in a sealed vial, intended strictly for in vitro testing and laboratory research. Follistatin 344 is the 344–amino acid isoform of human follistatin, a secreted glycoprotein that binds and neutralises members of the TGF-β superfamily, notably activins and myostatin (GDF-8). In experimental models, Follistatin 344 has been widely studied for its roles in muscle biology, tissue growth and repair, fertility, fibrosis and metabolic regulation. The Euro-Gen product is marketed as high-purity research-grade material for laboratory use only; it is not an approved medicine, food or cosmetic and is not for human or veterinary administration.

Bnefits

Provides a defined 1 mg quantity of Follistatin 344 per vial for reproducible in vitro and preclinical research.
Represents the well-characterised 344–amino acid isoform of human follistatin, widely used in studies of activin and myostatin signalling.
Useful as a tool protein to investigate muscle growth and atrophy pathways, tissue regeneration, fibrosis, reproductive endocrinology and metabolic regulation.
Supplied as a lyophilised, research-grade protein with high claimed purity (typically >95–98% by SDS-PAGE/HPLC) suitable for biochemical and cell-based assays.
Lyophilised presentation enhances stability during transport and storage before controlled laboratory reconstitution.
Clearly designated for research use only, helping laboratories segregate experimental reagents from regulated medicinal products.

Indications

No approved therapeutic indications; Euro-Gen Follistatin 344, 1mg is not licensed as a medicine or medical device.
Intended exclusively for in vitro and preclinical research on TGF-β superfamily signalling, particularly activin and myostatin pathways.
Suitable for use as a tool protein in studies of skeletal muscle hypertrophy and atrophy, tissue repair, fibrosis, reproductive biology and metabolic disease models.
May be used in cell culture, biochemical binding assays, and ethically approved animal models under appropriate institutional governance.
Not for human or veterinary injection, ingestion, inhalation, topical application or any other route of bodily administration.

Composition

Active research ingredient: recombinant human Follistatin 344 protein (FS344).
Length: 344 amino acids corresponding to the full-length human follistatin-1 precursor minus signal peptide, depending on construct.
Typical molecular weight: approximately 37–40 kDa for the polypeptide backbone, higher when glycosylated.
Glycoprotein nature: contains N-linked glycosylation sites; degree and pattern of glycosylation depend on expression system (e.g. E. coli vs. mammalian expression).
Binds and neutralises activins (e.g. activin A, activin B) and myostatin (GDF-8) in experimental systems.
Supplied as lyophilised powder; exact excipients (e.g. mannitol, trehalose, buffer salts) may vary by batch and are typically specified on the technical datasheet rather than consumer label.

Formulation

Lyophilised recombinant protein in a sterile, sealed glass vial containing a nominal 1 mg of Follistatin 344.
Research-grade material, generally supplied in carrier-free or low-carrier format to allow flexible experimental use.
Intended for reconstitution in an appropriate sterile laboratory-grade solvent or buffer (e.g. water for injection, PBS or specialised assay buffer) by trained personnel.
Formulated and labelled solely as a research reagent and not as a pharmaceutical dosage form for clinical use.

Packaging

Single 1 mg Follistatin 344 lyophilised protein vial with rubber stopper and crimped cap, labelled with product name, Euro-Gen branding and research-only designation.
Secondary protective packaging (e.g. cardboard carton or padded mailer) used for shipment to minimise breakage and environmental stress.
Accompanying online information typically includes basic structural and functional overview, storage guidance and safety disclaimers; no patient leaflet is provided as the product is not intended for therapeutic use.

Usage

For in vitro testing and laboratory research only; handle exclusively by suitably qualified and authorised laboratory personnel.
Do not inject, ingest, inhale or apply to humans or animals; any form of bodily administration is strictly prohibited and outside the product’s intended purpose.
Before opening, visually inspect the vial to ensure the container and lyophilised cake appear intact; do not use if there is evidence of damage, moisture ingress or contamination.
Reconstitute the lyophilised protein with an appropriate sterile laboratory-grade diluent (e.g. sterile water, buffer) according to institutional SOPs and required experimental concentration.
Gently swirl or invert to dissolve; avoid vigorous shaking that may denature the protein. If necessary, allow time for complete dissolution at recommended temperature.
Prepare aliquots of reconstituted protein to avoid repeated freeze–thaw cycles and clearly label with protein name, concentration, diluent, date and operator initials.
Use aseptic technique for all handling to minimise contamination and maintain experimental reliability.
Dispose of unused reconstituted protein, vials, syringes and any contaminated consumables as chemical/biological laboratory waste in accordance with institutional and regulatory requirements.

Contraindications

Any use involving administration to humans or animals (e.g. injection, ingestion, inhalation or topical application) is contraindicated and outside the stated purpose.
Should not be used as a substitute for licensed medicines, biologics or gene therapies targeting myostatin, activins or other TGF-β family members.
Not suitable for laboratories without appropriate infrastructure for safe handling and disposal of recombinant proteins and biological reagents.
Personnel with known allergies or sensitivities to proteins or specific excipients should minimise exposure and follow occupational health advice.
Not to be used in doping, physique enhancement or any context intended to circumvent anti-doping regulations in sport.

Adverse Effects

No formal adverse-effect profile exists for this commercial preparation in humans or animals because it is not intended for administration.
Accidental exposure (e.g. skin or eye contact, inhalation of dust/aerosol, or ingestion) may cause non-specific irritation or sensitisation; standard laboratory first-aid measures (rinsing, fresh air, medical evaluation if needed) should be followed.
Unauthorised self-administration or clinical use of research-grade Follistatin 344 may pose significant and unpredictable risks, including immune reactions, dysregulated growth, endocrine disturbances and off-target tissue effects; such use is strongly discouraged.
Laboratory workers should follow institutional risk assessments and use appropriate PPE (e.g. gloves, eye protection, lab coat) to reduce exposure.

Storage Conditions

Store unopened vials in a cool, dry, dark place; many laboratories keep lyophilised recombinant proteins refrigerated (2–8 °C) or frozen (≤ −20 °C) according to internal SOPs.
Protect from direct sunlight, excessive heat and moisture; avoid repeated temperature cycling.
After reconstitution, store aliquots at recommended temperatures (e.g. 2–8 °C for short-term, ≤ −20 °C for longer-term) and avoid repeated freeze–thaw cycles to minimise degradation.
Keep vials and reconstituted solutions out of reach of unauthorised personnel and clearly segregated from medicinal products, food and cosmetics.
Dispose of expired or compromised material as laboratory waste in compliance with local regulations and institutional policies.

Duration

Not applicable. Euro-Gen Follistatin 344, 1mg has no authorised clinical treatment regimen; any use in humans or animals as therapy would be outside its intended research-only scope.

Onset

Not applicable in a clinical sense. In experimental models, the timing of observed biological effects depends on the system used, dosing, exposure time and endpoints measured, and cannot be extrapolated to human therapeutic onset or efficacy.